Clinical Trial

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Completed
View on ClinicalTrials.gov →
Summary
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-05; most recent amendment 2026-02-20.
Status change: Recruiting → Completed 2026-02-20
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT07008963
Lead Sponsor AstraZeneca
Conditions Metastatic Breast Cancer
Enrollment 48 participants
Start Date 2025-07-31
Primary Completion 2025-11-28 (estimated)
Study Completion 2025-11-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-23